Ultra-Processed Foods Linked to Early Signs of Parkinson's Disease
Ultra-processed foods are associated with a rogues' gallery of health problems, including elevated risk for obesity, dementia, type 2 diabetes, and heart disease.
Yet despite experts' warnings, ultra-processed foods are satisfying, cheap, and easy, making them popular across much of the world. In the US, more than half of all calories adults consume at home now come from ultra-processed foods.
As researchers race to keep up, the list of suspected risks continues to grow.
According to an international team of researchers who analyzed decades of records from tens of thousands of health workers, people who eat a lot of ultra-processed foods are more likely to have early signs of Parkinson's disease than those who don't.
This does not prove causation, but it does reveal a noteworthy association, especially in the broader context of health concerns related to ultra-processed foods. It also adds to mounting evidence that diet is key to brain health.
"Eating a healthy diet is crucial as it has been associated with a lower risk of neurodegenerative diseases, and the dietary choices we make today can significantly influence our brain health in the future," says co-author Xiang Gao, a nutritional epidemiologist with the Institute of Nutrition at Fudan University in Shanghai.
In the new study, researchers focused on signs of Parkinson's disease that appear before more specific symptoms develop, which can include body pain, constipation, depressive symptoms, excessive daytime sleepiness, and an impaired sense of smell. At this stage, while patients may not have characteristic features of the disease, neurodegeneration may have already begun.
"There's growing evidence that diet might influence the development of Parkinson's disease. Our research shows that eating too much processed food, like sugary sodas and packaged snacks, might be speeding up early signs of Parkinson's disease," Gao says.
The researchers conducted a longitudinal analysis using data from the Nurses' Health Study and the Health Professionals Follow-Up Study, letting them track details about the diet and health of nearly 43,000 people for up to 26 years.
This sample included men and women with an average age of 48 years, who had no history of Parkinson's disease. The subjects had received regular medical exams and completed biennial health questionnaires, which Gao and his colleagues reviewed for early signs of Parkinson's disease.
Subjects also submitted responses to surveys at two- to four-year intervals, offering insight into their dietary habits. Researchers used this to estimate each subject's average daily ingestion of ultra-processed foods, as defined by the Nova classification system for food processing.
The study covered several types of ultra-processed foods, including sauces, spreads, or condiments; artificially or sugar-sweetened beverages; packaged savory snacks; packaged sweets; snacks or desserts; yogurt or dairy-based desserts; and animal-based products.
Subjects were split into five groups based on their consumption of ultra-processed foods. Those in the highest group ate 11 or more servings per day on average, while the lowest group averaged fewer than three daily servings.
The researchers adjusted for factors such as age, alcohol intake, body mass index, caffeine intake, physical activity, and tobacco smoking, among others.
Subjects who ate 11 or more daily servings of ultra-processed foods were 2.5 times likelier to have at least three early signs of Parkinson's disease compared with subjects who ate fewer than three servings per day, the authors report.
Higher consumption of ultra-processed foods was linked with increased risk of almost all early signs of Parkinson's disease used in this study, they found, with the exception of constipation.
There are some important caveats to these findings. They show an association between ultra-processed foods and increased risk for early signs of Parkinson's disease, but more research is needed to clarify the nature of the relationship.
The focus on early signs of Parkinson's disease also involves some ambiguity, as the authors acknowledge, since these are potential hints of the condition rather than definitive indicators.
Many of the early signs – body pain, for example, or daytime sleepiness – are common as people age and don't necessarily herald Parkinson's disease.
All of these features considered in composite, however, are "strongly predictive" of subsequent Parkinson's disease diagnoses, the researchers write.
"Choosing to eat fewer processed foods and more whole, nutritious foods could be a good strategy for maintaining brain health," Gao says.
"More studies are needed to confirm our finding that eating less processed food may slow down the earliest signs of Parkinson's disease."
The study was published in Neurology.
AI Discovers Suspected Trigger of Alzheimer's, And Maybe a Treatment
One Stage of Sleep Seems Critical For Reducing Risk of Dementia
World First: US Baby Treated With Personalized CRISPR Gene-Editing
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Trump cuts threaten ‘irreplaceable' Harvard stockpile of human feces, urine
Kept frozen by liquid nitrogen inside laboratories at Harvard University are more than 1.5 million biospecimens that have mere 'weeks' left until they spoil. As Harvard fights the Trump administration in court over the suspension of nearly $3 billion in federal funding, soon there won't be enough money left to keep the freezers running. The nearly 50 years of collected human feces, urine, blood, tumors and even toenail clippings could have consequential implications for the future health of Americans, and yet, they're at risk of being lost if funding slashed by the Trump administration isn't restored. The mother lode collection housed at Harvard has supported generations-long chronic disease risk studies that have fundamentally shaped major scientific and medical advancements. Read more: Funding cuts, lawsuits, foreign students: The latest on Trump's war with Harvard University The studies have lead to major breakthroughs, including links between cigarettes and cardiovascular disease and alcohol consumption and breast cancer. The research also uncovered the dangers of trans fats, which the U.S. has now largely restricted. The biological samples collected during the studies are 'irreplaceable,' according to Walter Willett, a professor of epidemiology and nutrition at the Harvard T.H. Chan School of Public Health and one of the most sought-after nutritionists internationally. And some of the study participants could even die before the next check-in period, he said. 'No other institution in the world has this data,' Willett wrote in a May 30 court affidavit detailing the impacts of federal funding cuts on his research. Read more: Over 12,000 Harvard alums lend weight to court battle with Trump in new filing The money can't be replaced with private funding, Willett said, and Harvard has told him it won't be able to supplement lost dollars. Willett filed his affidavit last month as part of a lawsuit in which Harvard faculty members are suing the Trump administration. President Donald Trump has gone after the world's wealthiest higher education institution and its funding in the name of antisemitism, claiming Harvard has failed to protect Jewish students, particularly in the wake of the war in Gaza. Willett's research is funded by two federal grants from the National Cancer Institute at the National Institutes of Health. On May 6, he was informed the funding had been terminated for both the Nurses' Health Study and Health Professionals Follow-Up Study. The Nurses' Health Study, which began with its first installment in 1976, followed by Willett's involvement in 1989, started tracking a cohort of 116,000 women in order to understand how 'diets and lifestyle relate to the risk of developing cancer,' Willett's affidavit said. In addition to collected biological samples, much of the data comes from questionnaires filled out by study participants every two years. The Nurses' Health Study has associated circulating sex hormones and postmenopausal breast cancer risk; connected higher vitamin D levels linked with lower risks of both colon polyps and colon cancer; and played a role in discovering genetic variations involved in cancers and cancer-related factors. The Health Professionals Follow-up Study is parallel research that has been tracking the diets of 52,000 adult men who have been diagnosed with cancer from all states in America. 'This study collects data about heart attacks, cancer and other conditions that share risk factors with heart disease, such as dementia and Parkinson's disease,' Willett wrote. 'Dozens of other grants studying many diseases have used the dataset collected by this study.' Read more: 'We are not just fighting for Harvard': For alums, this year feels different The male-focused study, which has also been used for women's research, has unearthed the harmful effects of trans fat; made connections between healthy plant foods and lower cardiovascular risk; linked dietary patterns and prostate cancer risk; and associated olive oil benefits with a lower risk of dying from dementia. There is another element of urgency in addition to the uncertain future of the biological samples: Willett says some participants may die before researchers are able to follow up with them next year for new information on their physical and cognitive functions. 'The termination of my grants thus jeopardizes our chance to collect data from the living study participants who have voluntarily contributed personal information over the last four decades,' Willett wrote. 'This would deprive all Americans from the benefits of knowledge about diet, other aspects of lifestyle, and use of medications that enhance their possibilities of living longer and healthier lives.' Since April, the Trump administration has launched a series of attacks against Harvard. Nearly $3 billion in federal funding has either been cut or frozen, and there was also a wave of federal research grant terminations. The Harvard T. H. Chan School of Public Health announced in April that it was facing a 'significant budget crisis' resulting in layoffs and the non-renewal of two building leases. Since then, every one of the school's direct federal grants have been terminated and the school has even taken to social media to ask for donations. Federal funding makes up 46% of Harvard Chan School's budget. Read more: All Ivy League schools are supporting Harvard lawsuit — except these 2 U.S. Education Secretary Linda McMahon has also told the institution that the federal government would be barring Harvard University from acquiring new federal grants while the university continues to refuse to comply with the administration's demands for change on its campus. Harvard President Alan Garber wrote in a letter to U.S. Secretary of Education Linda McMahon that they share the same 'common ground,' but the university 'will not surrender its core, legally-protected principles out of fear.' Read more: Funding cuts, lawsuits, foreign students: The latest on Trump's war with Harvard University Garber pushed back on the administration via a lawsuit in April. Harvard argues that its constitutional rights have been violated by the government's threats to pull billions of dollars in funding if the school doesn't comply with demands for an overhaul. Following a further $450 million in announced cuts, the university amended its lawsuit. 'No government — regardless of which party is in power — should dictate what private universities can teach, whom they can admit and hire, and which areas of study and inquiry they can pursue,' the suit reads. Due to the federal cuts, Harvard announced that it has committing $250 million of 'central funding' to support research impacted by suspended and canceled federal grants. All Ivy League schools are supporting Harvard lawsuit — except these 2 Embassies directed to resume processing Harvard University student visas Over 12,000 Harvard alums lend weight to court battle with Trump in new filing 'We are not just fighting for Harvard': For alums, this year feels different What a monk, a librarian and a dentist have to do with Harvard's fight with Trump Read the original article on MassLive.

Yahoo
19 hours ago
- Yahoo
US appeals court confirms patent validity of Acadia's Parkinson's drug
(Reuters) -Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, its drug for hallucinations and delusions associated with Parkinson's disease. The decision supports a December 2023 ruling from the U.S. District Court of Delaware, ensuring the patent remains protected in Acadia's legal battle against India-based drugmaker MSN Laboratories. The appeals court followed a precedent that says an earlier patent claim cannot be invalidated by a later one if they share the same priority date. "We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for Nuplazid, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for Nuplazid 34 mg capsule formulation into 2038," said CEO Catherine Owen Adams. This decision comes after another favorable ruling for Acadia regarding its formulation patent for Nuplazid. The court supported Acadia's claims of infringement and validity in its legal case against Aurobindo Pharma and other companies. The U.S. FDA approved Nuplazid for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis in 2016.
Yahoo
a day ago
- Yahoo
Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ('Jupiter' or the 'Company'), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, today announced the official commercial launch of Nugevia™, its consumer longevity product line. The launch represents a pivotal milestone in Jupiter's strategy to generate near-term revenue while maintaining momentum in its clinical pipeline. Nugevia's debut comes as global demand accelerates for scientifically validated wellness solutions that extend healthspan and enhance mental and metabolic resilience. Backed by over eight years of pharmaceutical development, powered by Jupiter's proprietary JOTROL™ micellar delivery technology, Nugevia products bring a clinical-grade standard to the nutraceutical space. 'The launch of Nugevia is the natural next step in translating our science into broad, real-world impact,' said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. 'By building on the same proprietary technology platform that underpins our prescription drug development, we're delivering a differentiated consumer offering with unmatched bioavailability and scientific credibility.' A New Standard in Evidence-Based Supplementation Nugevia's first three formulations—targeting mitochondrial support, mental clarity, and "beauty from within"—will be sold via a direct-to-consumer (DTC) model starting in Q3 2025. Each product integrates JOTROL™, Jupiter's enhanced resveratrol formulation that demonstrated a 9x improvement in bioavailability during clinical trials. JOTROL™ is also the foundation of Jupiter's ongoing therapeutic programs in Parkinson's and Alzheimer's disease. Unlike typical single-ingredient supplements, Nugevia features precision-engineered "intelligent stacking" of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization. 'We cracked the code on resveratrol's widely published issue with bioavailability, and now we're unlocking its potential beyond the clinic,' added Rosén. 'Consumers are seeking longevity solutions that are both credible and effective. Nugevia meets that demand.' Strategic Synergy with Core Pipeline The Nugevia launch adds a new dimension to Jupiter's value proposition as a dual-path company—advancing clinical-stage therapies for CNS disorders while monetizing its platform in the booming longevity market, projected to reach $8 trillion by 2030. The Company expects this initiative to provide a self-reinforcing commercial engine, with revenues from Nugevia supporting ongoing clinical trials and expanding its shareholder-aligned business model. 'Nugevia represents more than a product launch—it's a strategic engine for growth,' said Rosén. 'By leveraging our core science in a consumer format, we're creating a near-term revenue stream that supports our therapeutic pipeline and strengthens long-term shareholder value. It's smart capital allocation with real scientific impact.' A digital press kit, including high-resolution product imagery and key brand information, is available at . About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company's pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be found on the Company's website About JOTROL Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer's Disease trial, and Yui et al., Friedreich's Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer's Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL toward a Phase IIa trial in Parkinson's Disease. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations, including the Company's ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 'approximates,' 'believes,' 'hopes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'plans,' 'will,' 'would,' 'should,' 'could,' 'may' or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company's final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contact: Dave GentryRedChip Companies, Inc.1-407-644-42561-800-RED-CHIP (733-2447)JUNS@